PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
12193067-2	2002	Based on the same core structure, we have developed four small-molecule ET receptor antagonists, ABT-627 (atrasentan), ABT-546, A-182086 and A-192621, which exhibit differences in selectivity for ET(A) and ET(B) receptors.	Atrasentan	106-116	endothelin receptor type A	Rattus norvegicus	196-201	
16563629-7	2006	injections of selective antagonists of ET(A) (atrasentan, 3-10 mg/kg) or ET(B) (A-192621, 5-20 mg/kg) receptors caused significant inhibitions lasting 1-2.5h (peaks approximately 65-90%).	Atrasentan	46-56	endothelin receptor type A	Rattus norvegicus	39-44	
31326653-9	2019	Atrasentan treatment increased fetal weight, circulating endothelin and placental ETA message, and unexpectedly increased local complement activation in placenta (C3 deposition) but not C3a in circulation, suggesting endothelin controls local placental complement activation in normal pregnancy.	Atrasentan	0-10	endothelin receptor type A	Rattus norvegicus	82-85	
11404288-4	2001	Five-day oral dosing with the selective ET(A)-receptor antagonist ABT-627 (~2 mg. kg(-1).	Atrasentan	66-73	endothelin receptor type A	Rattus norvegicus	40-45	
28005706-6	2017	One group of CKD + Ca/P/VitD rats was given the ETA receptor antagonist atrasentan (10 mg/kg/day) for 6 weeks.	Atrasentan	72-82	endothelin receptor type A	Rattus norvegicus	48-51	
29846112-2	2018	The present study examined whether chronic endothelin A (ETA) receptor blockade with atrasentan prevents the progression of renal injury in two models of DN with preexisting renal disease that exhibit an increased renal ET-1 system compared with nondiabetic rats: streptozotocin-treated Dahl salt-sensitive (STZ-SS) and type 2 diabetic nephropathy (T2DN) rats.	Atrasentan	85-95	endothelin receptor type A	Rattus norvegicus	43-70	
24373834-5	2014	Alternatively, ETA receptor blocker (atrasentan, 5 mg kg(-1) day(-1) in drinking water) was added to the combined RAS blockade.	Atrasentan	37-47	endothelin receptor type A	Rattus norvegicus	15-18	
25656942-7	2015	Selective blockade of ETA receptors by atrasentan (5 mg kg(-1) day(-1)) abolished the pressor response elicited by CSA or CSA plus indomethacin.	Atrasentan	39-49	endothelin receptor type A	Rattus norvegicus	22-25	
25775254-0	2015	Endothelin A receptor antagonist, atrasentan, attenuates renal and cardiac dysfunction in Dahl salt-hypertensive rats in a blood pressure independent manner.	Atrasentan	34-44	endothelin receptor type A	Rattus norvegicus	0-21	
25775254-4	2015	In this study, we investigated whether atrasentan, an ETA receptor antagonist, has renal and cardiovascular effects independent of RAS inhibition.	Atrasentan	39-49	endothelin receptor type A	Rattus norvegicus	54-57	
25255392-0	2015	Endothelin A receptor blocker atrasentan lowers blood pressure by the reduction of nifedipine-sensitive calcium influx in Ren-2 transgenic rats fed a high-salt diet.	Atrasentan	30-40	endothelin receptor type A	Rattus norvegicus	0-21	
25255392-10	2015	CONCLUSION: BP-lowering effect of chronic atrasentan treatment in TGRs was mainly caused by reduced Ca influx through L-type voltage-dependent calcium channels due to missing ETA receptor-dependent vasoconstriction and attenuated angiotensin II-dependent vasoconstriction.	Atrasentan	42-52	endothelin receptor type A	Rattus norvegicus	175-178	
22494993-3	2012	Candesartan (selective AT1R antagonist) and ABT-627 (selective ET(A)R antagonist) were perfused, beginning 15 minutes before ischemia.	Atrasentan	44-51	endothelin receptor type A	Rattus norvegicus	63-69	
25300759-2	2014	METHODS: In rats made uremic by renal ablation, we examined the effects of addition of the endothelin-A receptor antagonist atrasentan to a previously examined combination of enalapril (angiotensin converting enzyme inhibitor) and paricalcitol (vitamin D receptor activator) on cardiac and renal parameters.	Atrasentan	124-134	endothelin receptor type A	Rattus norvegicus	91-112	
19188829-0	2009	ETA receptor blockade with atrasentan prevents hypertension with the multitargeted tyrosine kinase inhibitor ABT-869 in telemetry-instrumented rats.	Atrasentan	27-37	endothelin receptor type A	Rattus norvegicus	0-3	
21191784-3	2011	Half of the animals in each group received the ET(A)-selective antagonist, ABT-627 (atrasentan; orally), beginning immediately after hyperglycaemia was confirmed.	Atrasentan	75-82	endothelin receptor type A	Rattus norvegicus	47-52	
19104001-9	2009	Treatment with ABT-627, an endothelin A receptor antagonist, or N(G)-propyl-L-arginine, an NO synthase 1 inhibitor, prevented the increase in U(Na)V observed in female rats.	Atrasentan	15-22	endothelin receptor type A	Rattus norvegicus	27-48	
19188829-3	2009	Atrasentan is a potent and selective endothelin (ETA) receptor antagonist that lowers blood pressure and affects tumor growth.	Atrasentan	0-10	endothelin receptor type A	Rattus norvegicus	49-52